• Western blot analysis of 293T, using CBL antibody (STJ22913) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% non-fat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.
  • Western blot analysis of mouse thymus, using CBL antibody (STJ22913) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% non-fat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 1s.
  • Immunohistochemistry analysis of paraffin-embedded human prostate using CBL antibody (STJ22913) at dilution of 1:200 (40x lens). Perform microwave antigen retrieval with 10 mM PBS buffer pH 7. 2 before commencing with immunohistochemistry staining protocol.
  • Immunohistochemistry analysis of paraffin-embedded mouse lung using CBL antibody (STJ22913) at dilution of 1:200 (40x lens). Perform microwave antigen retrieval with 10 mM PBS buffer pH 7. 2 before commencing with immunohistochemistry staining protocol.
  • Immunofluorescence analysis of K-562 cells using CBL rabbit polyclonal antibody (STJ22913) at dilution of 1:300 (40x lens). Blue: DAPI for nuclear staining.
  • Immunofluorescence analysis of NIH/3T3 cells using CBL rabbit polyclonal antibody (STJ22913) at dilution of 1:300 (40x lens). Blue: DAPI for nuclear staining.
  • Immunofluorescence analysis of PC-12 cells using CBL rabbit polyclonal antibody (STJ22913) at dilution of 1:300 (40x lens). Blue: DAPI for nuclear staining.
  • Immunoprecipitation analysis of 600 Mu g extracts of mouse thymus cells using 3 Mu g CBL antibody (STJ22913). Western blot was performed from the immunoprecipitate using CBL antibody at a dilution of 1:1000.

Anti-CBL antibody (850-906) (STJ22913)

SKU:
STJ22913

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/IP
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-CBL (850-906) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and Immunoprecipitation research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:1000-1:5000
IHC-P 1:50-1:100
IF/ICC 1:100-1:500
IP 1:500-1:1000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CBL
Gene ID: 867
Uniprot ID: CBL_HUMAN
Immunogen Region: 850-906
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 850-906 of human CBL (NP_005179.2).
Immunogen Sequence: AATASPQLSSEIENLMSQGY SYQDIQKALVIAQNNIEMAK NILREFVSISSPAHVAT
Post Translational Modifications Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70. Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK. Ubiquitinated, leading to its degradation via the proteasome. Ubiquitination is negatively regulated by IFT20.
Function Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Ubiquitinates SPRY2. Ubiquitinates EGFR. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA.
Protein Name E3 Ubiquitin-Protein Ligase Cbl
Casitas B-Lineage Lymphoma Proto-Oncogene
Proto-Oncogene C-Cbl
Ring Finger Protein 55
Ring-Type E3 Ubiquitin Transferase Cbl
Signal Transduction Protein Cbl
Database Links Reactome: R-HSA-1059683
Reactome: R-HSA-1236382
Reactome: R-HSA-1295596
Reactome: R-HSA-1433559
Reactome: R-HSA-182971
Reactome: R-HSA-2173789
Reactome: R-HSA-5637810
Reactome: R-HSA-5654726
Reactome: R-HSA-5654727
Reactome: R-HSA-5654732
Reactome: R-HSA-5654733
Reactome: R-HSA-6807004
Reactome: R-HSA-8849469
Reactome: R-HSA-8856825
Reactome: R-HSA-8856828
Reactome: R-HSA-8875360
Reactome: R-HSA-912631
Reactome: R-HSA-9680350
Reactome: R-HSA-9706369
Reactome: R-HSA-9706377
Cellular Localisation Cytoplasm
Cell Membrane
Cell Projection
Cilium
Golgi Apparatus
Colocalizes With Fgfr2 In Lipid Rafts At The Cell Membrane
Alternative Antibody Names Anti-E3 Ubiquitin-Protein Ligase Cbl antibody
Anti-Casitas B-Lineage Lymphoma Proto-Oncogene antibody
Anti-Proto-Oncogene C-Cbl antibody
Anti-Ring Finger Protein 55 antibody
Anti-Ring-Type E3 Ubiquitin Transferase Cbl antibody
Anti-Signal Transduction Protein Cbl antibody
Anti-CBL antibody
Anti-CBL2 antibody
Anti-RNF55 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance